Sun Pharmaceutical Industries Share Price Today (SUNPHARMA)
TODAY IN ONE LINE
SUNPHARMA fell 1.2% on light volume, in line with Nifty's -0.8% move, reaching near its 52-week high of ₹1966.5.
With a market cap of ₹4.64 L Cr., it trades at a P/E of 41.01. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Sun Pharmaceutical Industries flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 25.6% YoY
- ●Consistent GrowthEPS compounded at 10.6% over 3 years
- ●Quarterly OutperformanceLatest quarter Sales up 12.8% and Profit up 13.6%
- ●High Capital EfficiencyROCE of 20.5% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 16.0%
- ●Healthy Operating MarginsOPM is structurally strong at 28.2%
- ●High Promoter HoldingPromoters hold 54.5% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 12.9% outpacing sales growth of 8.4%
Latest Sun Pharmaceutical Industries News
What changed recently?
Recent events, corporate actions, and announcements.
Sun Pharmaceutical Industries Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Sun Pharmaceutical Industries Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Sun Pharmaceutical Industries Ltd trades at a P/E of 41.01× and P/B of 5.63×, against the Healthcare sector median P/E of 40.48×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Sun Pharmaceutical Industries Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Sun Pharmaceutical Industries Ltd — derived from the live tape, not yesterday's close.
Sun Pharmaceutical Industries Ltd last traded at ₹1,937.5 with an intraday range of ₹1,925.2–₹1,951.8 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1937.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2004.33 | +66.83 | +3.45% |
| R3 | 1977.73 | +40.23 | +2.08% |
| R2 | 1964.77 | +27.27 | +1.41% |
| R1 | 1951.13 | +13.63 | +0.70% |
| PIVOT | 1938.17 | 0.67 | 0.03% |
| CURRENT | 1937.50 | — | — |
| S1 | 1924.53 | -12.97 | -0.67% |
| S2 | 1911.57 | -25.93 | -1.34% |
| S3 | 1897.93 | -39.57 | -2.04% |
| S4 | 1871.33 | -66.17 | -3.42% |
SUNPHARMA is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹1925.2–₹1950.3
Trading Below opening range, showing Bearishness
Sun Pharmaceutical Industries Ltd financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Sun Pharmaceutical Industries Ltd — consolidated or standalone — with margins, YoY growth and key ratios inline.
Sun Pharmaceutical Industries Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4.64 L Cr. and reported EPS of ₹47.87.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 52,578 | 58,462 ▲ 11.2% |
| Sales Growth YoY %Derived | 8.42% | 11.19% |
| Other Income | 1,965 | 1,972 ▲ 0.3% |
| Total Income | 54,543 | 60,434 ▲ 10.8% |
| 10,747 | 11,544 ▲ 7.4% | |
| Gross ProfitDerived | 41,831 | 46,918 ▲ 12.2% |
| Gross Margin %Derived | 79.56% | 80.25% |
| 26,559 | 29,187 ▲ 9.9% | |
| EBITDA (Operating Profit)Derived | 15,272 | 17,731 ▲ 16.1% |
| OPM %Derived | 29.05% | 30.33% |
| 2,129 | 1,969 ▼ 7.5% | |
| Profit Before Tax (PBT) | 13,752 | 15,119 ▲ 9.9% |
| 2,772 | 3,554 ▲ 28.2% | |
| Effective Tax %Derived | 20.16% | 23.51% |
| Total Profit for Period | 10,965 | 11,509 ▲ 5.0% |
| Less: Non-controlling Interests | 36 | 29 ▼ 18.1% |
| Net Profit (Owner's PAT)Derived | 10,929 | 11,479 ▲ 5.0% |
| Net Profit Margin %Derived | 20.79% | 19.64% |
| PAT Growth YoY %Derived | 14.12% | 5.04% |
| Earnings Per Share (EPS ₹) | 45.55 | 47.84 ▲ 5.0% |
| Diluted Shares Outstanding (Cr) | 240 | 240 ▲ 0.0% |
| Share of Profit from Associates/JVs | -15 | -56 ▼ 264.0% |
| Other Comprehensive Income (Net of Tax) | 912 | 3,827 ▲ 319.4% |
| Total Expenses (incl. D&A & Interest) | 40,791 | 45,315 ▲ 11.1% |
| Material Cost % of RevenueDerived | 12.27% | 12.64% |
| Employee Cost % of RevenueDerived | 18.97% | 19.53% |
| Other Cost % of RevenueDerived | 31.55% | 30.39% |
| Interest Coverage (x)Derived | 54.88x | 43.65x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 26,489 | 29,066 ▲ 9.7% | 32,838 ▲ 13.0% | 33,498 ▲ 2.0% | 38,654 ▲ 15.4% | 43,886 ▲ 13.5% | 48,497 ▲ 10.5% | 52,578 ▲ 8.4% | 58,462 ▲ 11.2% | |
| Sales Growth YoY %Derived | — | 9.73% | 12.98% | 2.01% | 15.39% | 13.53% | 10.51% | 8.42% | 11.19% | |
| Other Income | 839 | 1,025 ▲ 22.3% | 636 ▼ 38.0% | 836 ▲ 31.4% | 922 ▲ 10.3% | 635 ▼ 31.1% | 1,354 ▲ 113.4% | 1,965 ▲ 45.1% | 1,972 ▲ 0.3% | |
| Total Income | 27,328 | 30,091 ▲ 10.1% | 33,473 ▲ 11.2% | 34,334 ▲ 2.6% | 39,576 ▲ 15.3% | 44,520 ▲ 12.5% | 49,851 ▲ 12.0% | 54,543 ▲ 9.4% | 60,434 ▲ 10.8% | |
7,425 | 7,869 ▲ 6.0% | 9,230 ▲ 17.3% | 8,690 ▼ 5.9% | 10,352 ▲ 19.1% | 10,662 ▲ 3.0% | 10,663 ▲ 0.0% | 10,747 ▲ 0.8% | 11,544 ▲ 7.4% | ||
| Gross ProfitDerived | 19,065 | 21,197 ▲ 11.2% | 23,607 ▲ 11.4% | 24,808 ▲ 5.1% | 28,303 ▲ 14.1% | 33,224 ▲ 17.4% | 37,834 ▲ 13.9% | 41,831 ▲ 10.6% | 46,918 ▲ 12.2% | |
| Gross Margin %Derived | 71.97% | 72.93% | 71.89% | 74.06% | 73.22% | 75.70% | 78.01% | 79.56% | 80.25% | |
13,457 | 14,889 ▲ 10.6% | 16,617 ▲ 11.6% | 16,317 ▼ 1.8% | 17,905 ▲ 9.7% | 21,577 ▲ 20.5% | 24,811 ▲ 15.0% | 26,559 ▲ 7.0% | 29,187 ▲ 9.9% | ||
| EBITDA (Operating Profit)Derived | 5,608 | 6,308 ▲ 12.5% | 6,990 ▲ 10.8% | 8,491 ▲ 21.5% | 10,398 ▲ 22.5% | 11,647 ▲ 12.0% | 13,023 ▲ 11.8% | 15,272 ▲ 17.3% | 17,731 ▲ 16.1% | |
| OPM %Derived | 21.17% | 21.70% | 21.29% | 25.35% | 26.90% | 26.54% | 26.85% | 29.05% | 30.33% | |
1,067 | 1,094 ▲ 2.6% | 2,095 ▲ 91.5% | -2,085 ▼ 199.5% | -2,296 ▼ 10.1% | 2,530 ▲ 210.2% | 2,301 ▼ 9.1% | 2,129 ▼ 7.5% | 1,969 ▼ 7.5% | ||
| Profit Before Tax (PBT) | 3,479 | 3,810 ▲ 9.5% | 5,010 ▲ 31.5% | 2,799 ▼ 44.1% | 4,481 ▲ 60.1% | 9,408 ▲ 109.9% | 11,088 ▲ 17.9% | 13,752 ▲ 24.0% | 15,119 ▲ 9.9% | |
845 | 601 ▼ 28.9% | 823 ▲ 36.9% | 515 ▼ 37.4% | 1,076 ▲ 109.0% | 848 ▼ 21.2% | 1,439 ▲ 69.8% | 2,772 ▲ 92.6% | 3,554 ▲ 28.2% | ||
| Effective Tax %Derived | 24.29% | 15.77% | 16.42% | 18.39% | 24.00% | 9.01% | 12.98% | 20.16% | 23.51% | |
| Total Profit for Period | 2,608 | 3,208 ▲ 23.0% | 4,172 ▲ 30.1% | 2,272 ▼ 45.5% | 3,389 ▲ 49.2% | 8,513 ▲ 151.2% | 9,610 ▲ 12.9% | 10,965 ▲ 14.1% | 11,509 ▲ 5.0% | |
| Less: Non-controlling Interests | 447 | 542 ▲ 21.4% | 407 ▼ 25.0% | -631 ▼ 255.1% | 117 ▲ 118.5% | 39 ▼ 66.2% | 34 ▼ 14.5% | 36 ▲ 6.1% | 29 ▼ 18.1% | |
| Net Profit (Owner's PAT)Derived | 2,162 | 2,665 ▲ 23.3% | 3,765 ▲ 41.3% | 2,904 ▼ 22.9% | 3,273 ▲ 12.7% | 8,474 ▲ 158.9% | 9,576 ▲ 13.0% | 10,929 ▲ 14.1% | 11,479 ▲ 5.0% | |
| Net Profit Margin %Derived | 8.16% | 9.17% | 11.47% | 8.67% | 8.47% | 19.31% | 19.75% | 20.79% | 19.64% | |
| PAT Growth YoY %Derived | — | 23.31% | 41.25% | -22.87% | 12.70% | 158.91% | 13.01% | 14.12% | 5.04% | |
| Earnings Per Share (EPS ₹) | 9.01 | 11.11 ▲ 23.3% | 15.69 ▲ 41.2% | 12.10 ▼ 22.9% | 13.64 ▲ 12.7% | 35.32 ▲ 158.9% | 39.91 ▲ 13.0% | 45.55 ▲ 14.1% | 47.84 ▲ 5.0% | |
| Diluted Shares Outstanding (Cr) | 240 | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | 240 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -25 | -1 ▲ 94.3% | -15 ▼ 915.8% | -12 ▲ 16.9% | -17 ▼ 34.1% | -48 ▼ 189.6% | -38 ▲ 19.8% | -15 ▲ 60.0% | -56 ▼ 264.0% | |
| Other Comprehensive Income (Net of Tax) | 523 | 1,680 ▲ 221.1% | 2,121 ▲ 26.2% | -146 ▼ 106.9% | 557 ▲ 481.6% | 2,257 ▲ 305.0% | 1,142 ▼ 49.4% | 912 ▼ 20.1% | 3,827 ▲ 319.4% | |
| Total Expenses (incl. D&A & Interest) | 23,849 | 26,281 ▲ 10.2% | 28,464 ▲ 8.3% | 31,534 ▲ 10.8% | 35,095 ▲ 11.3% | 35,112 ▲ 0.0% | 38,763 ▲ 10.4% | 40,791 ▲ 5.2% | 45,315 ▲ 11.1% | |
| Material Cost % of RevenueDerived | 16.85% | 19.90% | 16.80% | 18.37% | 18.24% | 17.72% | 14.24% | 12.27% | 12.64% | |
| Employee Cost % of RevenueDerived | 20.26% | 20.53% | 19.38% | 20.49% | 18.89% | 18.90% | 19.44% | 18.97% | 19.53% | |
| Other Cost % of RevenueDerived | 30.54% | 30.70% | 31.23% | 28.22% | 27.43% | 30.26% | 31.72% | 31.55% | 30.39% | |
| Interest Coverage (x)Derived | 7.94x | 8.20x | 16.31x | 45.33x | 64.81x | 53.01x | 43.89x | 54.88x | 43.65x |
Sun Pharmaceutical Industries segment analysis : revenue and profit mix.
Disclosed business segments at Sun Pharmaceutical Industries with their share of revenue and profit, switchable between consolidated and standalone reporting.
Sun Pharmaceutical Industries discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Sun Pharmaceutical Industries Ltd.
Our AI distills the core fundamental drivers supporting Sun Pharmaceutical Industries Ltd, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Sun Pharmaceutical Industries Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 28.20% substantially outpaces pharmaceutical sector peers significantly
High ROCE 20.50% and ROE 16.00% demonstrate efficient capital deployment consistently
Promoter holding 54.50% signals strong founder confidence and long-term commitment
Low debt-to-equity 0.06x ensures financial flexibility and fortress balance sheet
TTM EPS grew 25.6% YoY, demonstrating strong earnings momentum and profitability
Key Risks.
P/E 39.03x substantially exceeds peer median, suggesting premium valuation risk
Dividend yield 0.82% may disappoint income-focused investors seeking higher returns
Latest quarterly EPS grew 26.2% YoY yet PAT rose only 13.6%, signaling earnings volatility
Stock price near 52-week high 1962.50, limiting near-term upside potential
Net profit margin 18.56% TTM declined from historical levels, indicating margin compression
Flip Conditions.
Valuation risk. a P/E above 53 (~1.3× the sector multiple of 40.5) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 11% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.41%.
Sun Pharmaceutical Industries Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Sun Pharmaceutical Industries Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Sun Pharmaceutical Industries Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Sun Pharmaceutical Industries Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Sun Pharmaceutical Industries Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Sun Pharmaceutical Industries Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Sun Pharmaceutical Industries Ltd stood at 59.2% of traded volume, against a 20-day average of 58.7%.
Sun Pharmaceutical Industries announcements: results, concalls, ratings, M&A.
Filings Sun Pharmaceutical Industries sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Sun Pharmaceutical Industries files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 153 documents below.
Press Release
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 15, 2026, titled "Sun Pharma receives approval…
Analysts/Institutional Investor Meet/Con. Call Updates
Sun Pharmaceutical Industries Limited has informed the Exchange about Schedule of meet
Investor Presentation
Sun Pharmaceutical Industries Limited has informed the Exchange about Investor Presentation
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Submission of Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
Investor decks & rating reports.
Sun Pharmaceutical Industries dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Sun Pharmaceutical Industries has declared, sequenced by announce and record date.
Sun Pharmaceutical Industries corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Sun Pharmaceutical Industries Ltd: business, sector, key facts.
What Sun Pharmaceutical Industries Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Sun Pharmaceutical Industries Ltd operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: SUNPHARMA, BSE: 524715.
Sun Pharmaceutical Industries Limited (Sun Pharma) is a global pharmaceutical company headquartered in Mumbai, India. Established in 1983, the company operates across the entire pharmaceutical value chain, encompassing research and development, manufacturing, and marketing of a diverse portfolio of pharmaceutical products.
Sun Pharma's core business revolves around the development, manufacturing, and marketing of both branded and generic formulations. Their product portfolio spans a wide range of therapeutic areas, including but not limited to central nervous system treatments, dermatological products, cardiovascular medications, oncology drugs, and treatments for neuropsychiatric, gastroenterological, and infectious diseases. They also cater to various other therapeutic segments such as diabetology, pain management, respiratory ailments, and women's health.
A significant aspect of Sun Pharma's operations is the production of Active Pharmaceutical Ingredients (APIs). These APIs are the fundamental building blocks of many medications and Sun Pharma manufactures a substantial range, including those used in anti-cancer therapies, peptide-based drugs, steroids, hormones, and immunosuppressants. This vertical integration allows for greater control over the supply chain and cost-effectiveness.
The company offers its formulations in various forms, including tablets, capsules, injectables, inhalers, topical applications (ointments and creams), and liquids. Beyond generic medications, Sun Pharma also markets specialty medications and antiretroviral drugs, along with over-the-counter (OTC) products. This diversification helps cater to a broad spectrum of patient needs and market segments.
In essence, Sun Pharma's business model is built upon a foundation of comprehensive pharmaceutical capabilities, covering the entire spectrum from API manufacturing to the marketing of finished dosage forms across various therapeutic categories. Their global presence and diversified product portfolio position them as a major player in the worldwide pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Sun Pharmaceutical Industries Ltd (SUNPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA)?
The current share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹1,937.5. Today, the stock has declined by ₹24.40 (1.24%), trading in a range of ₹1,925.2 to ₹1,951.8. The stock opened at ₹1,938 with a trading volume of 11,24,073 shares.
02Is Sun Pharmaceutical Industries Ltd stock a good investment for long-term?
Sun Pharmaceutical Industries Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,64,355.29 crores, P/E ratio of 41.01, ROE of 16.00%, and ROCE of 20.50%. The dividend yield stands at 0.82%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Sun Pharmaceutical Industries Ltd stock?
The 52-week high price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹1,966.5, while the 52-week low is ₹1,548. Currently trading at ₹1,937.5, the stock is 93.1% away from its 52-week low and 1.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Sun Pharmaceutical Industries Ltd stock at the current price?
Whether to buy Sun Pharmaceutical Industries Ltd stock at ₹1,937.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 41.01 and P/B ratio of 5.63. Today's performance shows a loss of 1.24%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Sun Pharmaceutical Industries Ltd and when is the next dividend?
Sun Pharmaceutical Industries Ltd offers a dividend yield of 0.82%, which means for every ₹100 invested at the current price of ₹1,937.5, you can expect to receive approximately ₹0.82 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd's key financial metrics include: P/E Ratio: 41.01, P/B Ratio: 5.63, ROE: 16.00%, ROCE: 20.50%, Dividend Yield: 0.82%, EPS: ₹47.87, Book Value: ₹348.31, and Debt-to-Equity: 0.06. The company's market cap stands at ₹4,64,355.29 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Sun Pharmaceutical Industries Ltd stock performing today in the market?
Sun Pharmaceutical Industries Ltd stock opened at ₹1,938 and is currently trading at ₹1,937.5, showing a decline of ₹24.40 (1.24%). The intraday high is ₹1,951.8 and low is ₹1,925.2. The trading volume stands at 11,24,073 shares, indicating strong market participation today.
08What is the P/E ratio of Sun Pharmaceutical Industries Ltd and what does it indicate?
Sun Pharmaceutical Industries Ltd has a Price-to-Earnings (P/E) ratio of 41.01, which means investors are willing to pay ₹41.01 for every ₹1 of earnings. With an EPS of ₹47.87, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Sun Pharmaceutical Industries Ltd (SUNPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.